Currently, the most frequently administered drugs in the United States are medical gases such as NO, O2, and CO2 that have been around in health care for some time and are used daily for many medical purposes in hospitals including anesthesia, therapy and diagnosis, according to the U.S. FDA.
A medical gas is defined as one that is manufactured, packaged, and intended for administration to a patient in anesthesia, therapy, or diagnosis. Medical gases are used within hospital settings for many purposes. The departments that use medical gases in hospitals include operating rooms, per-communicators, recovery rooms, debridement rooms, obstetrics and gynecology wards, ICU wards, and general wards.
There are seven kinds of gases commonly used in health care: oxygen, nitrogen, nitrous oxide, argon, helium, carbon dioxide and compressed air. Carbon makes strong bonds that give drugs their shape and readily releases those bonds, letting molecules emit stored energy, while its ability to maintain four bonds at once makes it the periodic table’s working horse. Carbon dioxide is a so-called ‘gasotransmitter’ inside the body that sends signals to the brain besides balancing the partial pressure of oxygen in blood and the local blood supply, besides affecting other vital functions. Medically, carbon dioxide (CO2) is typically used for anesthesia and to inflate the abdominal cavity and colon for laparoscopy and colonoscopy.
In addition, it is also used for laboratory culture of bacteria (anaerobic bacteria). According to a Grand View Research Report1, in 2016 the global medical gas market size was valued at USD 7.5 billion and by 2024 is expected to witness a 9.0% compounded annual growth rate (CAGR). An increasing incidence of chronic diseases, an ever-growing geriatric population, and a rising demand for home healthcare and point of care products are some of the major factors behind the growth of the medical gases market. Therapeutic applications of medical gases are so important that this purpose alone held the largest market revenue in 2016. Aside from pure gases, such as oxygen, the most commonly used medical gas mixtures are Carbon Dioxide-Oxygen mixtures, which in 2016 showed the biggest market profits. These medical gas mixtures are also expected to gain a significant market share owing to their increasing use in therapeutic and diagnostic applications.
The potential growth of CO2 mixtures is probably due to its extensive use for the assessment of chronic respiratory diseases such as asthma or bronchitis… and its use in combination with radiation for cancer treatment. Moreover, CO2 is used for oxygenation and in anesthetic mixtures useful in procedures like renal dialysis, cardio-pulmonary bypass surgery or in the management of chronic respiratory obstruction after the obstruction has been removed.
With a global rise in respiratory diseases and cancer, the demand for medical CO2 mixtures is expected to increase in the near future. According to renown experts like Judy M. Delp, Ph.D. in physiology and professor at the Florida State University, there are several general positive health effects associated to CO2, namely:
- It has sedating effects over the central nervous system
- It increases blood flow through arteriolar/venous dilation, thus improving microcirculation
- It produces a rightward shift in the O2 dissociation curve, thereby increasing oxygen delivery at the cellular level and leading to better tissue/organ oxygenation
- It is a fat-dissolving compound.
One of the most important effects of CO2 on the body is that of increased vasodilation and oxygenation. A high CO2 concentration potentiates the S-shaped dissociation curve of hemoglobin (Hb) to release O2 , therefore increasing O2 unloading from hemoglobin from a normal 40% dissociation rate to 70% O2 dissociation rate. This increased O2 unloading results in better tissue oxygenation. Further, it has been shown that increased pCO2 promotes arteriolar dilation in various tissues, and it plays a key role in regulating cerebral blood flow2.
Although there are several ways of delivery, D’OXYVA® uses a non-invasive skin-delivery method of vaporized ultra-purified CO2, which has been shown in quality human clinical studies to be safer than inhalation, a routine delivery method in hospital settings. The CO2 gets mixed with water inside the device, producing an active solution of supersaturated CO2 and water (H2O) vapor that improves skin microcirculation and/or blood circulation after dissolving into the skin3.
Rapid and gentle transdermal delivery with the D’OXYVA light-weight and hand-held device has recorded improving the blood microcirculation or perfusion index (PI) by 33%* on average in all participants. After single 5–minute D’OXYVA® delivery on skin surface lasting results could be already measured 5 minutes afterwards and up to 4 hours4. while increasing O₂ saturation in comparison to controls up to 2 hours after application. Clinical data also showed a consistent significant decrease in systolic and diastolic blood pressure up to 240 minutes after a single treatment with D’OXYVA®. Moreover, transdermal CO2 has shown positive results in wound care in several D’OXYVA® clinical studies, even where other treatment modalities have failed5 while reporting on zero side effects. Finally, experts believe transdermal CO2 successfully improves organ function (pancreas, liver, brain, and kidneys) and general health status in patients with hypertension.
Circularity Healthcare was established with a core mission to radically change the standard of care and improve lives, while demonstrating the emerging concept of the Circular Carbon Economy with the help of influential global strategic relationships. Our pioneering patented and patent-pending biotech called D’OXYVA® (deoxyhemoglobin vasodilator) utilizes mini, single-use cartridges and ultra-purified CO2 molecules filled inside them, which are non-toxic and harmless to our bodies and the environment, making them eco-friendly and fully compliant with federally regulated health and transportation safety guidelines and laws.
Following our company’s guidelines is highly advised when using our products, as your health is our top priority. With D’OXYVA, you’re choosing a clean, tested method that utilizes technology for your benefit. Check out our amazing products now and discover the right method to radically improve your quality of life and feel confident about the solution you’re using.
Carbon dioxide is sourced either naturally from deep underground wells or from capturing atmospheric, industrial and transportation emissions. Check out one of the latest carbon capture technologies from the world’s largest energy company, Aramco by visiting a Better Future.
Reference(s)
A Brief History of Medical Gases in Respiratory Care (CDC)
The history of respiratory protection traces back as far as Pliny the Elder (23-79 AD), a Roman philosopher and naturalist, who made use of loose animal bladder skins to filter dust from being inhaled while crushing cinnabar, which is a toxic, mercuric sulfide mineral used at the time for pigmentation in decorations.
Medical Gases and Equipment Market to See Huge Growth by 2030 (Medgadget)
The global medical gases and equipment market is exhibiting steady growth with the surge in demand from hospitals, home care settings, pharmaceutical companies, and other healthcare facilities. A recent study by Fact.MR states that the medical gases and equipment market is anticipated to grow at over 8% CAGR during the forecast period between 2020 and 2030.
Bibliography
1. Medical Gas Market Size & Share | Global Industry Report, 2014-2024. https://www.grandviewresearch.com/industry-analysis/medical-gases-market.
2. CV Physiology | Metabolic Mechanisms of Vasodilation. https://www.cvphysiology.com/Blood%20Flow/BF008.
3. Introducing D’OXYVA – What is D’OXYVA? D’OXYVA https://doxyva.com/about-doxyva/.
4. D`OXYVA Relief from neuropathic pain. D`OXYVA https://doxyva.com/complete-fast-advanced-painless-relief-from-neuropathic-pain/.
5. Puruhito, I. et al. D’OXYVA® Medical Device, a Potentially Cost-Efficient and Safe Adjuvant Therapy for Diabetic Ulcers: A Pilot Study. J Vasc Surg (2019).
